SRx Health Solutions, Inc. (NYSE American: SRXH) issues frequent press releases and SEC-referenced announcements that document its transition toward a digital-asset treasury operating model and its planned acquisition of EMJ Crypto Technologies Inc. (EMJX). The news flow provides insight into how the company is reshaping its strategy around a Gen2 digital-asset treasury platform that uses quantitative models, artificial intelligence and systematic risk controls.
Recent news items describe the definitive agreement to acquire EMJX, stockholder approval for a future name change to EMJX, Inc. and a planned ticker change to EMJX upon closing of the transaction. Company announcements also cover the deployment of an initial allocation of capital into digital assets such as Bitcoin and Ethereum, which the company characterizes as part of a measured, model-driven treasury management approach rather than short-term speculation.
Other SRXH news highlights enhancements to the EMJX platform, including integration of OpenAI large language models for research and risk decision support and the use of prediction-market probability data to strengthen its internal risk-intelligence framework. Governance and capital-markets updates appear regularly, such as the appointment of new directors with experience in cannabis, capital markets and cryptocurrency treasury strategies, amendments to the company’s charter to increase authorized shares, and private placements of preferred stock and warrants.
SRXH news releases also address NYSE American listing matters, including notifications of stockholders’ equity deficiencies and acceptance of the company’s plan to regain compliance with continued listing standards. For investors tracking SRXH, the news feed offers a consolidated view of transaction milestones, treasury activities, platform development and regulatory communications. Monitoring this page helps readers follow how the company’s proposed combination with EMJX progresses and how its digital-asset treasury strategy evolves over time.
SRX Global (NYSE American: SRXH) announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company developing medical countermeasures against synthetic drugs like fentanyl.
ARMR’s lead candidate ARMR-100, in a Phase 1/2 trial, has generated an anti-fentanyl immune response in humans with favorable safety and aims to provide 6–12 months of protection, with the next trial phase planned for late 2026.
SRX Global (NYSE American: SRXH), formerly SRx Health Solutions, closed its acquisition of EMJ Crypto Technologies (EMJX) and launched an AI-driven capital allocation platform focused on high-conviction operating companies and assets.
EMJX’s Gen2 digital-asset treasury and Halo brands now operate under SRX Global, which has already invested in Astro Capital, Opendoor Technologies, Uber Technologies and Optimi Health.
SRx Health Solutions (NYSE American: SRXH) and EMJ Crypto Technologies (EMJX) announced the acquisition of 4.99% of Smartkem (NASDAQ: SMTK) via a shelf takedown. The company also bought convertible preferred securities in a non-brokered private placement.
SRx has a definitive merger agreement with EMJX and has filed a Form S-4 registration statement with the SEC for stock to be issued in the proposed transaction. Investors are urged to read the Registration Statement and Information Statement/Prospectus when available. The communication does not constitute an offer or solicitation to buy or sell securities.
SRx Health Solutions (NYSE American: SRXH) and EMJ Crypto Technologies (EMJX) updated their portfolio and merger progress.
The firms initiated a new investment in Uber Technologies, reduced their long position in Compass, trimmed short exposure to Bitcoin, and added selective international hedges as the EMJX stress model shifted to STRESS from MIXED, the first negative reading since April 4, 2026. SRx also filed a Form S-4 Registration Statement with the SEC related to its definitive merger agreement with EMJX.
SRx Health Solutions (NYSE American: SRXH) and merger partner EMJX have invested in Optimi Health (NASDAQ: OPTH), a commercial-stage pharmaceutical company producing GMP-grade psychedelic drug products such as psilocybin for mental health therapies.
The investment was identified by EMJX’s AI-driven platform, citing about 30% insider ownership, institutional participation, strong management insider IPO participation, and governance led by chairman John James (JJ) Wilson. Tailwinds include an April 2026 U.S. executive order to accelerate psychedelic drug development. SRx has filed a Form S-4 related to its proposed merger with EMJX.
SRx Health Solutions (NYSE American: SRXH) and merger partner EMJ Crypto Technologies announced board approval to dividend 75% of profits from the Company’s investment in Astro Investment XVII, an Astro Capital SPV holding stakes in SpaceX and other AI and space companies.
The Company has invested more than 10% of its investable capital in this SPV and plans to return capital to shareholders upon its wind down. SRx Health has filed a Form S-4 Registration Statement related to its proposed transaction with EMJX.
SRx Health Solutions (NYSE American: SRXH) reported fiscal Q2 2026 results for the quarter ended March 31, 2026.
Net revenue rose 23% quarter over quarter to $3.4 million, gross margin held near 37%, and gross profit reached $1.3 million. Operating loss improved to $(1.8) million and net loss to $(6.4) million. Adjusted EBITDA loss improved 44% to $(0.6) million. Cash increased to $20.5 million, aided by equity and preferred issuances. SRx highlighted an active cryptocurrency strategy that reduced losses versus a buy-and-hold approach and a pending EMJX acquisition expected to close by fiscal Q3.
SRx Health Solutions (NYSE American: SRXH) and EMJ Crypto Technologies announced an investment of more than 10% of SRXH's investable capital into Astro Investment XVII, an Astro Capital affiliate SPV holding investments in SpaceX and other AI and space companies.
The company highlighted AI and space as long-term growth themes and reported filing a Form S-4 Registration Statement with the SEC for its proposed merger with EMJ Crypto.
SRx Health Solutions (NYSE:SRXH) invested greater than 10% of its investable capital in Astro Investment XVII, an affiliate of Astro Capital, focusing on the convergence of AI and space. The transaction accompanies a proposed merger with EMJ Crypto Technologies and a Registration Statement on Form S-4 to register common stock.
The company said the investment reflects belief in long-term AI and space value and noted investors should review the Information Statement/Prospectus and SEC filings before making decisions.
SRx Health Solutions (NYSE: SRXH) and EMJ Crypto Technologies announced an update on their proposed merger and operational progress as of April 17, 2026. EMJX deployed $18 million into a Gen2 digital-asset treasury strategy, reporting a 5.69% March 2026 return versus a 4.98% S&P 500 decline (10.67% outperformance).
The companies filed a Form S-4 registration statement with the SEC; the EMJX platform will operate as a wholly owned subsidiary and Eric M. Jackson will join as an officer post-close.